12 Best Italian Stocks to Buy in 2025

7) Stevanato Group S.p.A. (NYSE:STVN)

Number of Hedge Fund Holders: 11

Average Upside Potential: ~14.3%

Stevanato Group S.p.A. (NYSE:STVN) is engaged in the design, production, and distribution of products and processes to offer integrated solutions for bio-pharma and healthcare industries. The company has its headquarters in Piombino Dese, Italy. For Q3 2024, Stevanato Group S.p.A. (NYSE:STVN)’s revenue went up by 2% (3% on a constant currency basis) as compared with the same period last year, to €277.9 million. This growth was aided by a 6% growth in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, offsetting a 15% fall in the Engineering Segment.

Notably, revenue from high-value solutions rose to 36% of total revenue in Q3 2024 as compared to 32% for the same period last year. This was fueled mainly by higher customer demand for high-performance syringes, and to a lesser extent, other products. While announcing its Q3 2024 results, Stevanato Group S.p.A. (NYSE:STVN) maintained its fiscal year 2024 revenue guidance and continues to expect revenue of between €1,090 million – €1,110 million.

Stevanato Group S.p.A. (NYSE:STVN)’s growth investments continue to accelerate, and in Q3 2024, its Latina project remained profitable at the gross profit level, while in Fishers, the company rolled out commercial production and generated its first commercial revenue. In Engineering, the actions taken by Stevanato Group S.p.A. (NYSE:STVN) helped to complete a handful of highly complex projects for key customers that were earlier delayed. Notably, the effects of destocking are anticipated to gradually improve into 2025, as the company sees some signs of stabilization in vial demand as customers work down inventories.